Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
10/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
22/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
29/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

04/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi
26/11/18	TxCell : près de sept millions d'actions apportées à l'OPAS
23/11/18	TXCell : Sangamo Therapeutics dépasse les 90%
16/11/18	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
ARGENX SE	+1.99%	+3.63%	+69.27%	+117.24%	55.19B
WUXI APPTEC CO., LTD.	+4.60%	+3.02%	+57.38%	+62.27%	45.75B
BIONTECH SE	-0.91%	-0.43%	-12.23%	-15.75%	22.98B
INSMED INCORPORATED	+1.63%	+0.31%	-7.26%	+380.65%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	-0.26%	-1.09%	+27.55%	-18.57%	16.26B
GENMAB A/S	+0.95%	+3.39%	+21.80%	-36.71%	15.42B
EXELIXIS, INC.	-1.48%	-3.73%	+17.65%	+156.66%	13.05B
PHARMAESSENTIA CORPORATION	+4.95%	+11.70%	+125.78%	+261.94%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.63%	-5.49%	+21.79%	-	12.37B
Average	+0.58%	+2.28%	+35.75%	+113.47%	23.8B
Weighted average by Cap.	+1.46%	+1.51%	+41.38%	+105.51%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile